#Microplastics are everywhere. Our latest editorial calls for more research to understand their impact on human health. nature.com/articles/s4159…

Great to see that tovorafenib, a RAF inhibitor, has been granted FDA accelerated approval for treatment of pediatric r/r BRAF+ low-grade #glioma. Approval was based on the phase 2 FIREFLY-1 trial, which we published last year in Nature Medicine! #pLGG nature.com/articles/s4159…

Check out our new story out in Nature Medicine today: a phase II study of nivolumab in dMMR/hypermutated gynecologic cancers together with my dear friend Claire Friedman MD . link.springer.com/article/10.103… brief summary (thread):

🌟NEW in Nature Medicine: In 6 patients w/ #RheumatoidArthritis, the CD19xCD3 BITE #blinatumomab ⬇️ disease activity & ⬇️ autoantibodies. Work led by #GeorgSchett Ricardo Grieshaber-Bouyer FAU Erlangen-Nbg. Similar n of 1 report in systemic sclerosis published earlier this week. nature.com/articles/s4159…

📢 Proud to see this important, timely comment by @DrLauraEsserman & Douglas Yee MD just published in Nature Medicine. I 💯 agree: Science & medical groups should stop holding conferences in anti-choice states. Abortion IS healthcare! #WomensRights Please RT! nature.com/articles/s4159…

Extremely proud to announce that our NEOPREDICT-Lung study on neoadjuvant PD-1 and LAG-3 inhibition in resectable NSCLC is now online in Nature Medicine . Without any doubt one the highlights of my career so far. nature.com/articles/s4159…

Our molecular therapies editor Anna Maria Ranzoni is attending #ASGCT24 in Baltimore this week. Reach out to her if you'd like to discuss your work!

#BiTE therapy for #rheumatoidarthritis: A pilot study shows promising results with #blinatumomab, but larger studies and deep phenotyping will be crucial to optimizing this approach. News & Views from Frances Humby& colleagues Guy's and St Thomas' King's College London nature.com/articles/s4159…

The search for authentic microbiome–disease relationships. A new study challenges the validity of previously reported microbial markers and serves as a wake-up call for the #microbiome research field. News and Views from Ruixin Zhu & colleagues nature.com/articles/s4159…

Refining #neoadjuvant #immunotherapy for resectable #NSCLC: Perioperative approaches are expanding, and new data show feasibility of co-targeting PD-1 and LAG-3. News and Views from Christine Lovly, MD, PhD, FASCO and Misty Dawn Shields Vanderbilt University Medical Center nature.com/articles/s4159…

Happy to report biomarkers in DESTINIY GC01 Nature Medicine. T-DXd response high if ctDNA+ while still activity observed in negative pts. Response regardless of KRAS, HER2, PIK3CA mt. ↓response in other RTKamp+. HER2 loss or topo1mt on PD. nature.com/articles/s4159… OncoAlert

Pemigatinib in previously treated solid tumors w/ activating FGFR1–FGFR3 GA Nature Medicine doi.org/10.1038/s41591… 🔎 FIGHT-207 basket 👉Fusions most responsive, but histology matters 👉C382R & in frameDel also responsive 👉BAP1: ORR⬆️ 👉TP53: ORR⬇️ ESMO - Eur. Oncology ILCA EASLnews

Our #Oncology editor @UlrikeHarjes will be attending #ESMOBreast24, reach out to her if you would like to meet!

Interim analysis of the phase 3 FLAMES trial, maintenance therapy with a #PARP inhibitor in patients with #OvarianCancer showed prolonged progression-free survival compared with placebo in all subgroups defined by #BRCA or homologous recombination status nature.com/articles/s4159…

Our new study is now out in Nature Medicine! We introduce DEPLOY, a deep-learning model that enhances the diagnosis of CNS tumor subtypes. DEPLOY predicts methylation profiles from H&E slide images for classification. #CancerResearch #AI #DeepLearning shorturl.at/gjCOR 1/n

“If we don’t get this election right, your wife, your daughter, your mother, we as women, will become collateral damage to your rage…I am asking you all, from the core of my being, to take our lives seriously" 💯 Nailed it. nytimes.com/2024/10/26/us/…

Vote on the issues most important to you But I teach on the history of medicine and public health, and I know for absolute certain that letting RFK Jr “go wild on health” would mean a lot of people will get very sick. People will die. All unnecessarily.

I am so tired of this kind of nonsense. "Extreme" is not a reasonable descriptor for Kennedy's views. Reasonable descriptors include: - incorrect - unsupportable - delusional (or delulu, if you prefer) - retrogressive - unscientific - willfully uninformed - denialist

Absolutely heartbreaking. Thank you ProPublica for continuing to publish important, well researched articles like this. The mainstream media could learn a thing or two from you. This election shouldn't be treated like a game. #MedTwitter